Phase 2 N=9 Ponatinib in Advanced NSCLC w/ RET Translocations
Non Small Cell Lung Cancer
Primary: Overall Response Rate — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Non-small Cell Lung Cancer Metastatic · Targetable Oncogenes (EGFR, ALK, ROS1)
Primary: 1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) — 19 percentage of participants
Phase 2 N=13 Sunitinib in Never-Smokers With Lung Adenocarcinoma
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Phase 2 N=96 Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
Phase 1 N=8 Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
Phase 3 N=376 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Phase 2 N=590 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer
Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib — 400; 400 mg
Phase 3 N=347 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Phase 2 N=20 Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Phase 2 N=42 Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Objective Response Rate (ORR) — 2 percentage of participants
Phase 2 N=62 Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
HER2-mutant Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 0; 6 Participants
Phase 2 N=37 Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Non Small Cell Lung Cancer
Primary: Progression Free Survival at 3 Months — 50.4 percentage of participants
Phase 2 N=33 Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
Non-small Cell Lung Cancer
Primary: The Percentage of Patients That Respond to Treatment — 46; 29 percentage of patients
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Phase 2 N=44 Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer · Brain Cancer
Primary: Median Survival — 11.8 months
Phase 2 N=66 A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=68 Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 10.7; 15.0; 25.0; 0.0 percentage of participants — p=0.94
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=37 Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Objective Response Rate — 10.8 percentage of participants
N/A N=4 Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Phase 2 N=1,066 An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Phase 2 N=124 LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Phase 2 N=19 Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
Non-small Cell Lung Cancer
Primary: Tumor Response by Direct RECIST Measurement — 0 participants
Phase 2 N=47 Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
ATM Gene Mutation · ATR Gene Mutation · BARD1 Gene Mutation
Primary: Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (MDVN) Participants — 4 percentage of participants
Phase 2 N=25 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
KIF5B-RET-Positive Adenocarcinoma of the Lung
Primary: Objective Response Rate (ORR) — 16.0 percentage of participants
Phase 2 N=3 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
Lung Cancer, Nonsmall Cell
Primary: The Number of Participants With an Objective Tumor Response Rate — 3 participants
Phase 2 N=140 LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants